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7 Abstract
8 Purpose: Cutaneous T-cell lymphomas (CTCL) are a hetero-
9 geneous group of malignancies that despite available therapies
10 commonly relapse. The emergence of combination epigenetic
11 therapies in other hematologic malignancies have made investi-
12 gation of such combinations in CTCL a priority. Here, we explore
13 the synergistic antiproliferative effects of romidepsin, an HDAC
14 inhibitor, and azacitidine, a demethylating agent, combination in
15 CTCL.
16 Experimental Design: The growth inhibition under combina-
17 tion treatment and single agent was explored by the MTT cell
18 viability assay and the Annexin V/propidium iodide (PI) apopto-
19 sis assay in different CTCL cell lines and tumor cells derived from
20 Sezary syndrome patients. Quantitative analysis of a dose–effect
21 relationship of romidepsin and azacitidine was done by the
22 CompuSyn software. Investigation of mechanism of action was
23 performed by ﬂow cytometry, immunoblotting, qRT-PCR arrays,
24 and chromatin immunoprecipitation. Global CpG methylation
26sequencing was utilized to study genome methylation alteration
27under the treatment modalities.
28Results: The combination of romidepsin and azacitidine exerts
29synergistic antiproliferative effects and induction of apoptosis
30involving activation of the caspase cascade in CTCL cell lines and
31tumor cells derived from Sezary syndrome patients. We identiﬁed
32genes thatwere selectively induced by the combination treatment,
33such the tumor suppressor gene RhoB that is linked to enhanced
34histone acetylation at its promoter region in parallel with pro-
35nounced expression of p21. Global CpGmethylation sequencing
36in a CTCL cell line and tumor cells demonstrated a subset of genes
37with a unique change in methylation proﬁle in the combination
38treatment.
39Conclusions: The synergistic antiproliferative effects of romi-
40depsin and azacitidine combination treatment justify further
41exploration in clinical trials for advanced CTCL. Clin Cancer Res;
421–12. 2015 AACR.
43
44 Introduction
45 Cutaneous T-cell lymphomas (CTCL) comprise a heteroge-
46 neous group of malignancies derived from skin-homing T cells.
47 The more common subtypes are mycosis fungoides, and Sezary
48 syndrome, an aggressive leukemic variant of CTCL (1). These two
49 subtypes account for approximately 70% to 75% of all cases (2).
50 Therapeutic options include skin-directed therapy and/or system-
51 ic therapy (3). The success rate ofmost available therapy regimens
52 ranges from 30% to 50%, but relapse is common and difﬁcult to
53 treat, and curative therapy remains elusive. Therefore, there is an
54 indisputable need for more successful treatment approaches for
55 advanced CTCL.
56 Romidepsin (F228 or desipeptide) is a potent bicyclic histone
57 deacetylase (HDAC) inhibitor approved by the FDA for the
59treatment of relapsed/refractory CTCL patients on the basis of
60twophase II clinical trials showing anoverall response rate of 34%
61to 35% (4).
62Azacitidine (5-azacitidine or Vidaza) is a cytotoxic cytidine
63analogue andDNAmethyltransferase inhibitor with antineoplas-
64tic activity (5). At lower concentrations, it is known to relieve the
65transcriptional repression of various tumor suppressor genes that
66were silenced via hypermethylation of their promoter region (6).
67It was approved by the FDA for the treatment of refractory
68myelodysplastic syndromes (7).
69In cancer, tumor suppressors are often downregulated by
70aberrant histone deacetylation and/or DNA methylation (8).
71HDAC inhibitors can synergize with demethylating agents to
72relieve this transcriptional repression (9). Moreover, combined
73epigenetic therapies have been shown to be effective in hemato-
74logic malignancies (10–13).
75Here, we demonstrate that the combination of romidepsin and
76azacitidine exerts synergistic antiproliferative effects by inducing
77apoptosis in CTCL cell lines as well as CD4þ T cells derived from
78Sezary syndrome patients with high tumor burden. We show the
79tumor suppressor gene RhoB as a potential regulator of the
80synergism, whose antineoplastic relevance has been described in
81other malignancies (14–16). Furthermore, our data suggest that
82the combination treatment results in a unique globalmethylation
83pattern in CTCL, whichmay contribute to increased efﬁcacy of the
84antiproliferative effects of the combination treatment in CTCL.
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87 Materials and Methods
88 Cell lines
89 MyLa, SeAx, and Hut78, well-established CTCL cell lines (17,
90 18), were cultured in RPMI1640 medium (Invitrogen) supple-
91 mented with 10% heat-inactivated FBS, glutamine (2 mmol/L),
92 and streptomycin (100 mg/mL) at 37C, 5% CO2, and 95%
93 humidity.Q5
94 Cell viability assay
95 TheMTT (Sigma-Aldrich) assaymeasures the activity of cellular
96 enzymes that reduce the tetrazolium dye to its insoluble form,
97 formazan, which under deﬁned conditions can reﬂect the number
98 of viable cells. This assaywas utilized tomeasure cell proliferation
99 in untreated and treated CTCL cell lines, Sezary syndrome
100 patients, and healthy donor PBL samples. The absorbance was
101 measured by spectrophotometry, using a 550 nm wavelength
102 ELISA reader.
103 Flow cytometry
104 FITC Annexin V Apoptosis Detection Kit II (BD Biosciences)
105 was utilized for ﬂow cytometry to determine the percentage of
106 cells that are actively undergoing apoptosis within the untreated
107 and treatedCTCL cell lines, Sezary syndromepatients, andhealthy
108 donor PBL samples. After designated treatment schedule, cells
109 were harvested and stained as instructed in manufacturer's
110 protocol.
111 Propidium iodide (PI; Sigma-Aldrich) was utilized as a DNA
112 stain for ﬂow cytometry. DNA content in cell-cycle analysis was
113 evaluated to differentiate necrotic, apoptotic, and normal cells in
114 the above described populations. The proportion of cells that
115 exhibited sub-G1 phase of the cell cycle indicates DNA degrada-
116 tion and apoptotic cell death. After the designated treatment time,
117 cells were harvested in 0.3mLof cold PBS and thenﬁxedwith cold
118 70% ethanol, left incubating on ice for 1 hour, and washed twice
119 with cold PBS. RNase A (10 mg/mL) was added to each sample
120 and incubated at 37C for 1 hour. Cells were acquired using a BD
122FACSCanto ﬂow cytometry using the FL2-A channel and analyzed
123with the FlowJo software 8.5.2.
124Western blot analysis
125Cells were washed twice with cold PBS and lysed at 4C in RIPA
126protein lysis buffer. The protein concentration of each samplewas
127determined by Bradford assay (Bio-Rad protein assay, Bio-Rad).
128Proteins were separated by SDS-PAGE using the NuPAGE SDS-
129PAGE Gel System on 4%–12% or 10% NuPage Bis-Tris gels (Life
130Technologies) under reducing conditions according to the man-
131ufacturer's instructions and transferred onto nitrocellulose mem-
132branes (Invitrogen). The following primary antibodies were used:
133anti-acetylatedH3 (#9649), anti-cleaved caspase-3 (#9664, rabbit
134monoclonal), anti-cleaved caspase-9 (#7237, rabbit monoclonal,
135anti-cleaved PARP (#5625, rabbit monoclonal), p21waf1/Cip1
136(#2946, mouse monoclonal), and anti-a-tubulin (#2125, rabbit
137monoclonal; Cell Signaling Technology). Bound antibodies were
138detected using ECL Western Blotting Detection Reagent (GE
139Healthcare).
140Immunohistochemistry
141After incubation of CTCL cell lines with romidepsin and
142azacitidine simultaneously for 48 hours, the samples were placed
143on the slides using the cytospin procedure, as previously pub-
144lished (19). After ﬁxation in 10% acetone, the slides were incu-
145bated with the RhoB primary antibody (C-5, mouse monoclonal,
146Santa Cruz Biotechnology), and then secondary antibody as
147suggested by manufacturer's protocol.
148Primary Sezary cells and healthy donor CD4þ T cells
149Sample collection and laboratory studies were in compliance
150with Institutional review board, ethics committee and conducted
151according to the Declaration of Helsinki Principles. All patients
152signed informed consent, approved by theUSZ ethical committee
153(EK647).
154Patients' and healthy donors' peripheral bloodwas collected in
155EDTA tubes. PBMCs were separated from whole blood by Ficoll
156density gradient, then CD4þ T cells were selected by MACS CD4þ
157negative selection kit (Miltenyi Biotec) per the manufacturer's
158protocol. After negative cell selection, CD4þ T cells were stimu-
159latedwith CD3/CD28Dynabeads (Life Technologies) in addition
160to IL2 (30 U/mL) and treated with/without romidepsin and/or
161azacitidine as described.
162Quantitative real-time reverse-transcriptase-PCR
163Total RNA was extracted after incubation with designated
164time of treatment or untreated cells using TRIzol according to
165the manufacturer's instructions (Invitrogen). Concentration
166was determined by NanoDrop spectrophotometer. A total of
1672 mg RNA was used for cDNA synthesis using Promega's
168Reverse Transcription System (Promega) according to the sup-
169plied protocols. Gene expression was quantiﬁed using the
170Universal SYBR Green Master (ROX; 04913914001; Roche)
171and the Viia7 system from Applied Biosystems. The primers
172for were purchased from Qiagen and Cell Signaling Technol-
173ogy. The qRT-PCR arrays (RT2 Proﬁler Cancer Drug Targets
174PCR Array) were purchased from SA Biosciences (Qiagen).
175Total RNA from untreated and treated samples was character-
176ized in technical triplicates, and the relative expression
177levels for each gene in single agent or combination treated
Translational Relevance
Potential synergistic effects between two important epige-
netic regulators are under investigation in phase I/II clinical
trials in refractory hematologic malignancies as well as solid
tumors. Nevertheless, studies exploring the potential syner-
gistic interactions and insight to the molecular mechanism of
such combination therapy is lacking in CTCL. In addition,
there has been no common functional mutation or genetic
aberration identiﬁed to be responsible for malignant trans-
formation of T cells in CTCL. In this study, we describe, the
synergistic effect of romidepsin and azacitidine in CTCL cell
lines and tumor cells derived fromSezary syndromepatients as
well as demonstrate the potential underlyingmechanisms and
global methylation proﬁle alterations effecting gene expres-
sionwith potential predictive value inCTCL. Finally, the lower
concentration of each drug administered in the combination
as compared with single agent might translate in a favorable
tolerability of this combination that will be explored in future
clinical trials.
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180 samples were plotted against DMSO in the Scatter plot. All
181 analyses were conducted in relative quantitation using the
182 DDCt-based method for calculation of relative quantitation
183 values (20).
185Chromatin immunoprecipitation-PCR
186DNA was immunoprecipitated with the MAGnify Chromatin
187Immunoprecipitation System (Life Technologies) as per theman-
188ufacturer's instructions. Selective enrichment was performed
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Figure 1.
Change in cell viability measured via
MTT colorimetric assay. A, dose–
response curves were explored for each
CTCL cell line (Hut78, MyLa, and SeAx,)
treated with romidepsin or azacitidine
for 24 and 48 hours. Values are deﬁned
as means converted to percentages
after normalization to untreated control;
error bars represent SD. B, median dose
effect (analogue of IC50) was calculated
for romidepsin and azacitidine at 24 and
48 hours for each CTCL cell line (HUT78,
MyLa, SeAx).Q8
Romidepsin and Azacitidine Synergize in CTCL
www.aacrjournals.org Clin Cancer Res; 2015 3
120
100
80
60
%
 C
el
l v
ia
bi
lit
y
%
 C
el
l v
ia
bi
lit
y
Romidepsin (nmol/L)/Azacitidine (mmol/L)
Romidepsin (nmol/L)/Azacitidine (mmol/L)
17.1%
15.7% 45.1% 14.7% 32.1%
48% 18.8% 21.4%
MyLa
SeAx
AzacitidineRomidepsinRomidepsin+azacitidine
AzacitidineRomidepsin
PI
Romidepsin+
azacitidine
DMSO
D
11.3 88.7 31.368.7
18.8 81.2 14.8 85.2 9.46 90.5
782255.944.1
90.59.54
DMSO
C
el
l c
ou
nt
Annexin V FITC
MyLa
SeAx
SeAx
R+A
Romidepsin
Azacitidine
MyLa
A B
C
PI
MyLa
R+A
Romidepsin
Azacitidine
Romidepsin + Azacitidine
0.625 nmol/L + 1.25 mmol/L
1.25 nmol/L + 2.5 mmol/L
2.5 nmol/L + 5 mmol/L
5 nmol/L + 10 mmol/L
SeAx
Romidepsin + Azacitidine
0.625 nmol/L + 1.25 mmol/L
1.25 nmol/L + 2.5 mmol/L
2.5 nmol/L + 5 mmol/L
5 nmol/L + 10 mmol/L
0.956
0.956
0.88
0.54
Fa CI
0.59
0.4
0.525
1.09
0.8
0.79
0.56
0.04
Fa CI
0.87
0.48
0.64
1.27
120
100
80
60
40
20
0
40
20
0.6
25
 nm
ol/
L +
 1.
25
 mm
ol/
L
1.2
5 n
mo
l/L
 + 
2.5
 mm
ol/
L
2.5
 nm
ol/
L +
 5 
mm
ol/
L
5 n
mo
l/L
 + 
10
 mm
ol/
L
10
 nm
ol/
L +
 20
 mm
ol/
L
0.6
25
 nm
ol/
L +
 1.
25
 mm
ol/
L
1.2
5 n
mo
l/L
 + 
2.5
 mm
ol/
L
2.5
 nm
ol/
L +
 5 
mm
ol/
L
5 n
mo
l/L
 + 
10
 mm
ol/
L
10
 nm
ol/
L +
 20
 mm
ol/
L
0
Figure 2.
Synergistic decrease in cell viability and
induction of apoptosis. A, constant ratio
analysis of combination treatment
demonstrated synergistic decrease in
cell viability as measured by MTT
colometric assay after 48 hours
incubation of MyLa and SeAx cell lines
with romidepsin (R) and/or azacitidine
(A) combination at different
concentration at a constant dilution ratio
of 1:2,000. B, fraction-affected (Fa) and
CI are explored after 48-hour incubation
with romidepsin and azacitidine
combination, CI<1 represents synergy.
Q9 C, MyLa and SeAx cells were treated for
48 hours with romidepsin (1.25 nmol/L)
and/or azacitidine (2.5 mmol/L) or
DMSO-only treated cells. Then,
induction of apoptosis wasmeasured by
ﬂow cytometry after FITC Annexin V/PI
staining (values in the right top
quadrants represent the percentages of
cells that were Annexin Vþ/PI plus
Annexin Vþ/PIþ). D, cell-cycle analysis,
sub-G1 population measured by ﬂow
cytometry after PI staining.
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191 using an antibody speciﬁc to histone H3 acetylated at K9 (Cell
192 Signaling Technology) and unspeciﬁc IgG (Cell Signaling Tech-
193 nology) as control. Then, we quantiﬁed the ratio of immunopre-
194 cipitated DNA over 10% input with primers speciﬁc to the RhoB
195 promoter region (forward primer: GGTTTCCCATTGGACGGCTA;
196 reverse primer: GCCTCGCTGAGCATACAAGA) by qRT-PCR, in
197 the MyLa cell line.
198 Next-generation DNA methylation sequencing
199 DNA was isolated using TRIzol, according to manufacturer's
200 instructions. Total of 3mg ofDNAwasused as input amount in the
201 Agilent SureSelectXTMethyl-Seq Target Enrichment System for
202 Illumina Multiplexed Sequencing protocol. Quality of the isolat-
203 ed DNA was assessed by an Agilent 2200 Tapestation. DNA was
204 sheared using a S220 Focused-ultrasonicator (Covaris). Bisulﬁte
205 conversion was done using EZ DNA Methylation Kit (Zymo
206 Research) according to the manufacturer's instructions.
207 Sequencing was performed by Illumina Hiseq 2000. We
208 sequenced 0.25 lane per sample paired end 100 bp. Average
209 coverage was 20. Data analysis was done using "Bismark" for
210 aligning and "Methylkit" for differential methylation quantiﬁca-
211 tion. P values were adjusted for multiple hypotheses testing
212 according to the false discovery rate method. Data have been
213 uploaded to NCBI GEO GSE66732.
214 Compounds and reagents
215 Romidepsin and azacitidine were provided by CelgeneQ6 .
216 Statistical analysis
217 The median dose effectQ7 [ref. 21; or half the maximal inhibitory
218 concentration (IC50)] values for each cell line at different time
219 points were determined using CompuSyn software (22) based on
220 the quantitative analysis of dose–effect relationships on multiple
221 drugs or enzyme inhibitors by Chou and Talalay (23). Combi-
222 national index (CI) values were calculated to conﬁrm synergy. CI
223 <1 indicates synergistic effects, CI¼ 1 indicates themean additive
224 effect of the drugs, and CI > 1 represents an antagonistic effect.
225 Statistically signiﬁcant differences within different experiments
226 were determined using Student t test with P < 0.05 as minimal
227 signiﬁcance.
228 Results
229 Romidepsin and azacitidine combination treatment synergize
230 in the induction of apoptosis in CTCL
231 We observed a concentration- and time-dependent decrease in
232 cell viability as measured by the MTT colormetric assay, in all cell
233 lines at 24 and 48 hours after incubation with a range of romi-
234 depsin or azacitidine concentrations (Fig. 1A).We determined the
235 IC50 for romidepsin and azacitidine in all cell lines (MyLa, SeAx,
237andHut78) at 24 and 48-hour time point utilizing theCompuSyn
238software. IC50 of romidepsin was within the range of what was
239previously reported in preclinical studies (24). The calculated
240IC50 of azacitidine varied between cell lines but remained mostly
241>5 mmol/L even after 48 hours of treatment (Fig. 1B).
242Similar pattern in time- and dose-dependent decrease in cell
243viability was observed in all three cell lines. Therefore, we con-
244tinued our experiments with MyLa and SeAx cell lines. We next
245analyzed the dose-dependent growth inhibition under romidep-
246sin and azacitidine combination treatment and single agent,
247normalized to control, at different concentration levels with a
248constant dilution ratio of 1:2,000 at 48 hours via MTT assay (Fig.
2492A). Moreover, the combination index (CI) was calculated using
250the CompuSyn software with CI<1 representing synergy (Fig. 2B),
251as detailed in the Materials and Methods section. The combina-
252tion treatments were synergistic at different combination con-
253centrations especially at lower concentrations. The lack of synergy
254at the highest concentration is likely due the fact that potent drugs,
255such as romidepsin, can become highly cytotoxic at high con-
256centrations and are not an accurate representation of the combi-
257nation effects on cell viability (25). The concentration of azaci-
258tidine, as a hypomethylating agent, in our experiments correlates
259with the concentration used in many preclinical experiments in
260various cell lines (26, 27).
261Further experiments with the CTCL cell lines were performed
262with romidepsin 1.25 nmol/L and/or azacitidine 2.5mmol/L, as at
263these concentrations, the combination had the lowest CI reﬂect-
264ing a higher level of synergy at 48 hours. MyLa and SeAx cells
265exhibited a higher percentage of apoptosis under romidepsin 1.25
266nmol/L and azacitidine 2.5 mmol/L combination treatment com-
267pared with each single agent added together as analyzed by ﬂow
268cytometry after Annexin V/PI staining (Fig. 2C). Moreover, under
269the combination treatment, a higher percentage ofMyLa and SeAx
270cells demonstrated a shift to the sub-G1 population, as measured
271by ﬂow cytometry after PI staining, further conﬁrming the anti-
272proliferative effects (Fig. 2D).
273Romidepsin and azacitidine combination treatment synergize
274in inducing apoptosis in CD4þ T cells derived from Sezary
275syndrome patients but not on healthy donor CD4þ T cells
276To analyze the growth-inhibitory effects of the combination
277treatment on Sezary cells, we separated CD4þ T cells from the
278peripheral blood of Sezary syndrome patients and two healthy
279donors, as described in the Materials and Methods section. Some
280studies suggest that treatment with hypomethylating agents
281should precede treatment with HDAC inhibitors for optimum
282synergy (12, 28). Therefore, based on the in vitro experiments and
283preliminary experiments on tumor cells derived from Sezary
284syndrome patients that were treated with different concentration
285of romidepsin and/or azacitidine (data not shown), optimum
Figure 3.
Assessment of cell viability and apoptosis in Sezary syndrome (SS) patients, healthy donor (HD) derived cells, and caspase cascade activation. A, signiﬁcant
decrease in cell viability in the combination treatment compared with single agents (P < 0.05) shown by MTT assay in 4 Sezary syndrome–derived tumor
cells. B, signiﬁcant increase in apoptosis in the combination treatment compared with single agents (P < 0.05) shown by ﬂow cytometry after FITC
Annexin V/PI staining (values in the right top quadrants represent the percentages of cells that were Annexin Vþ/PI plus Annexin Vþ/PIþ). C, grouped
graph depiction of induction of apoptosis in combination treatment versus single agent in 3 Sezary syndrome patient–derived cells compared with 2 helthy
donor–derived cells. Treatments in healthy donor–derived cells only resulted in low growth inhibition without additive toxicity by the combination.
D, cell-cycle analysis, sub-G1 population measured by ﬂow cytometry after PI staining in patient samples. E, increase in cleavage of caspase-9, caspase-3,
and PARP in the combination compared to single-drug or DMSO-treated cells in MyLa cell line and representative Sezary syndrome–derived patient cells.
R, romidepsin; A, azacitidine.
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288 antiproliferative effects were reached with azacitidine 2.5 mmol/L
289 for 4 days and romidepsin 2.5 nmol/L was added for the last 24
290 hours. This combination was used in the patient-derived samples
291 for further experiments.
292 A signiﬁcant synergistic effect on cell viability and induction of
293 apoptosis was evident, measured by the MTT assay (Fig. 3A) and
294 by ﬂow cytometry after Annexin V/PI staining (Fig. 3B and C,
295 P<0.05). To analyze the effects of this combination on CD4þ cells
296 derived from the peripheral blood of healthy donors, we incu-
297 bated CD4þ cells derived from healthy donors with the same
298 schedule and noted only low cytotoxicity without increased
299 growth inhibition under the combination treatment (Fig. 3C),
300 indicating that the combination has synergistic growth-inhibitory
301 effect on the tumor cells beyond increased cytotoxicity.
302 As demonstrated with the CTCL cell lines, a higher percentage
303 of CD4þ T cells derived from Sezary syndrome patients treated
304 with the combination showed a shift to the sub-G1 population,
305 further conﬁrming increased apoptosis (Fig. 3D). In addition, the
306 combination treatment compared with single agent resulted in
307 pronounced cleavage of caspase-9, caspase-3, and PARP analyzed
308 by Western blot analysis, as shown in CTCL cell line as well as a
309 representative patient sample (Fig. 3E).
310 Romidepsin and azacitidine combination treatment results in
311 reexpression of tumor suppressor RhoB in CTCL by enhancing
312 histone acetylation of its promoter region
313 To elucidate the synergistic epigenetic-modulatory effects of
314 histone deacetylation and DNA methylation on known dysregu-
315 lated cancer genes, we used the cancer drug target qRT-PCR array
316 to analyze the CTCL cell lines (MyLa, SeAx), treated with romi-
317 depsin 1.25 nmol/L alone, azacitidine 2.5 mmol/L alone, in
318 combination, or DMSO-treated cells for 48 hours. Analysis of
319 this dataset demonstrated that the gene expression proﬁle of the
320 tumor cells treated with the combination treatment is unique in
321 comparisonwith single agent, whichwasmore pronounced in the
322 MyLa cell line (Fig. 4A). Among top 5 genes that demonstrated
323 more than 4-fold signiﬁcant reexpression in the combination
324 treatment compared with the single treatments and vehicle, in
325 both cell lines, was theGTP-binding protein from the Rho protein
326 family, RhoB. This was also the only one that was consistently
327 differentially expressed in cell lines and inpatient-derived primary
328 cells. RhoB is suggested to be induced by genotoxic stress and
329 mediates proapoptotic effects on transformed cells (29). The
330 expression of RhoB is attenuated in many cancer derived cell
331 lines compared with their normal tissue counterparts (30).
332 We validated the signiﬁcant upregulation of RhoB in CD4þ
333 cells derived from Sezary syndrome patients upon combination
334 treatment inmost patients' samples (Fig. 4B, P < 0.05). Moreover,
335 previous studies have suggested that after genotoxic stress RhoB
336 expression is induced within in the ﬁrst few hours, and then is
337 attenuated prior to another cycle of higher expression (31). To
339analyze this pattern, we incubated the MyLa and SeAx cell lines
340with romidepsin and azacitidine and extracted RNA at 6, 24, and
34148 hours andmeasured the fold change in RhoB gene expression.
342RhoB expression was rapidly upregulated under the combination
343treatment in both cell lines as early as 6 hours, reaching a lower
344level at 24 hours prior to another cycle of upregulation again at 48
345hours (Fig. 4C). RhoB protein expression is illustrated by IHC in
346MyLa cell line (Fig. 4D).
347Our methyl-sequencing data showed no methylation in the
348CpG island of RHOB promoter region of vehicle-treated cells. In
349addition, it did not demonstrate any differential methylation of
350RhoB promoter region under the combination treatment com-
351pared with single-agent or untreated cells (data not shown).
352HDAC inhibitors have been shown to reactivate RhoB expression
353in lung (32), ovarian (33), and thyroid cancer (34). In Fig. 4E, we
354demonstrated more pronounced histone H3 acetylation in CTCL
355cell lines and a representative patient sample under the combi-
356nation treatment by Western blot analysis. We speculated that
357histone acetylation of the RhoBpromoter region is responsible for
358reactivation of RhoB in CTCL and hypomethylating agent further
359enhances this acetylation. To test this, we performedChIP-PCR by
360selective enrichment using an antibody speciﬁc to histone H3
361acetylated at K9 and unspeciﬁc IgG as control, and then we
362quantiﬁed the ratio of immunoprecipitated DNA over input with
363primers speciﬁc to the RhoB promoter region by qRT-PCR, in the
364MyLa cell line (see Materials and Methods). Figure 4F demon-
365strates the signiﬁcantly higher histone acetylation of the RhoB
366promoter region under the combination treatment compared
367with romidepsin alone correlating with a signiﬁcant decrease in
368cell viability by MTT assay (Fig. 4G) and more pronounced p21
369signal by Western blot analysis under the combination treatment
370(Fig. 4H). Therewas no change inhistoneH3acetylation in single-
371agent azacitidine-treated cells.
372The combination of romidepsin and azacitidine results in a
373speciﬁc global (CpG) methylation proﬁle alteration
374The marked activity of DNA-hypomethylating agents have been
375attributed to hypomethylation of key regulators of apoptosis and
376cell-cycle arrest (26,35). To identify the globalmethylationchanges
377under the combination treatment,MyLa cell lines andCD4þ T cells
378derived from a Sezary syndrome patient were treated with romi-
379depsin and azacitidine in combination or each agent alone.
380A principal component analysis of the global methylation
381datasets demonstrated distinct clustering of azacitidine-treated
382tumor cells, alone and in combination, which were distant from
383romidepsin alone and DMSO-treated cells (Fig. 5A). The percent-
384age of differentially methylated regions per chromosome analysis
385reveals a global CpG hypomethylation under azacitidine treat-
386ment, alone or in combination, but absent in romidepsin single
387agent–treated cells (Fig. 5B). Genome-wide CpG island methyl-
388ation proﬁling identiﬁed 1,956 genes shared between the
Figure 4.
Combination treatment results in reexpression of the tumor suppressor gene RhoB by enhanced histone acetylation of its promoter region. A, cancer drug targets
qRT-PCR array demonstrated a unique expression proﬁle with the combination treatment in the MyLa cell line (top) and SeAx cell line (bottom) after
48 hours. B, RhoB mRNA expression was analyzed by RT-PCR in CD4þ T cells derived from four Sezary syndrome (SS) patients (C) and in the CTCL cell lines
at 6, 24, and 48-hour time points demonstrating the cyclic expression of RhoB. D, RhoB expression by immunohistochemistry. E, H3 acetylation after treatment
with romidepsin (R) and/or azacitidine (A) or DMSOanalyzed byWestern blot analysis. F, H3 acetylation at the RhoB promoter region is signiﬁcantly increased in the
combination treatment versus single agent, analyzed by ChIP-PCR. G, parallel cell viability analysis by MTT assay. H, effect of combination therapy on
p21 protein analyzed by Western blot analysis.
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391 azacitidine and romidepsin with azacitidine treatments. A total of
392 285 genes were exclusive to the combination treatment (Fig. 5C).
393 Interestingly, pathway analysis by Metacore of the genes that are
395differentially methylated in the azacitidine and combination
396treatment revealedmany pathways involved in apoptosis, inﬂam-
397mation, and immune response.
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Figure 5.
Combination of romidepsin and azacitidine results in speciﬁc global methylation changes. A, principal component analysis demonstrated clustering of
azacitidine-treated cells, alone or in combination away from romidepsin alone or DMSO-treated cells. B, percentage of differentially methylated regions
per chromosome showed azacitidine alone or in combination causes a global CpG hypomethylation in the CTCL genome. C, a Venn diagram illustrated
CpG methylation changes of overlapping genes in different treatment groups with a subset of genes that are differentially methylated only in the combination
treatment (adjusted P < 0.05).
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400 Discussion
401 In many other malignancies, characteristic chromosomal
402 abnormalities have been identiﬁed as therapeutic targets, such
403 as bcr-abl fusion gene in chronic myelocytic leukemia (CML) and
404 BRAF status in melanoma. In CTCL, various cytogenetic studies
405 foundmultiple genetic alterations that recur in a subset ofmycosis
406 fungoides and/or Sezary syndrome patients (36–38). But few
407 common genetic variants including targetable mutations have
408 been identiﬁed (39).
409 Hence, over the past decade there has been an emergence of
410 studies exploring the involvement of epigenetic mechanisms that
411 contribute to the pathogenesis of CTCL (40–42). These data are
412 limited to only molecular assessments or identiﬁcation of epige-
413 netic changes as prognostic markers.
414 Potential synergistic effects between two important epigenetic
415 regulators: histone acetylation and DNA hypomethylation is
416 under investigation in phase I/II clinical trials in refractory lym-
417 phoid and myeloid malignancies as well as solid tumors (43).
418 Nevertheless, studies exploring the potential synergistic interac-
419 tions and insight to the molecular mechanism of such combina-
420 tion therapy is lacking in CTCL. In this study, we describe the
421 synergistic effect of romidepsin and azacitidine in CTCL cell lines
422 andCD4þT cells derived fromSezary syndromepatients aswell as
423 demonstrate the potential underlying mechanisms and global
424 methylation proﬁle alterations affecting gene expression. Our
425 data suggests combinationof romidepsin and azacitidine inCTCL
426 synergistically activates the caspase cascade–inducing apoptosis,
427 as compared with single-agent treatments at the same concentra-
428 tions. Moreover, the concentration of each drug administered in
429 the combination was almost 50% less than the IC50 of each agent.
430 Thismight translate in a favorable tolerability of this combination
431 that will be explored in future clinical trials.
432 Intriguingly, the combination induced the reexpression of the
433 tumor suppressor gene, RhoB, as early as 6 hours posttreatment.
434 This could be explained by the rapid induction of RhoB in
435 response to early stress to trigger pathways involved in DNA
436 damage response and cell death. RhoB is believed to be a central
437 factor in growth inhibition of transformed cells (15, 29, 44).
438 Investigations in multiple cancers have found that RhoB is rarely
439 mutated in cancer genomes (45). In addition, there is no known
440 aberrant methylation at its promoter region that could be respon-
441 sible for the loss of RhoB expression, as others (32) and we have
442 shown. Therefore, histone modiﬁcations or other transcriptional
443 regulatory mechanism may be responsible for the loss of RhoB
444 expression. Preclinical data suggest increased histone acetylation
445 at the RhoB promoter region results in its reexpression in lung
446 carcinoma and anaplastic thyroid cancer (30, 34). In our study,
447 the combination treatment resulted in signiﬁcant histone H3
448 acetylation at the promoter region of RhoB gene compared with
449 romidepsin alone suggestinghistone acetylation is responsible for
450 transcriptional activity of RhoB, which is further enhanced by the
451 hypomethylating agent azacitidine. This might be due to the fact
452 thatDNAhypomethylation results in amore accessible chromatin
453 for histone acetylation or due to DNA hypomethylation–inde-
454 pendent effects of azacitidine that could contribute to the syner-
455 gistic effects of the combination. It is suggested that RhoB pro-
456 motes cell-cycle arrest by controlling the expression of cell-cycle
457 regulators such as p21 (34). We observed an upregulation of p21
458 in cell lines and tumor cells derived from Sezary syndrome
459 patients. This might be RhoB dependent or due to RhoB playing
461a crucial role in the sensitization of the CTCL cells toDNAdamage
462and subsequent apoptosis. RhoB had a high expression under the
463combination treatment in the cancer drug target qRT-PCR array
464screen but there are other potential genes in this cancer drug target
465screening array that showed signiﬁcant change in their expression
466under the combination. For example, ErbB-3 was signiﬁcantly
467expressed under the combination treatment. This gene has been
468shown to play a role in sensitizing NSCLC cells to HDAC inhi-
469bitors (21). Additional detailed mechanistic experiments are
470required to better understand the role of these genes and their
471targets in CTCL.
472Genome-wide methylation analysis of the MyLa cell line and
473tumor cells derived from an Sezary syndrome patient revealed
474distinct clustering of azacitidine and combination treated cells as
475compared with romidepsin-treated or untreated cells. This is not
476surprising as the majority of genes differentially methylated
477between azacitidine and combination treatment are shared.
478Romidepsin has a small effect on hypomethylation and this is
479in line with reports demonstrating the role of HDAC inhibition
480increasing global DNA hypomethylation (46, 47). Interestingly,
481the combination treatment had an exclusive set of differentially
482methylated genes, which suggests speciﬁc pathways are involved
483in the synergistic action of romidepsin and azacitidine. The 285
484genes were involved in many signaling pathways including apo-
485ptosis, immune response, and inﬂammation. Overlap with the
486RT-PCR array for cancer target genes was not prominent, as this
487array is focused on mostly cancer-associated kinases. Further-
488more, there could be upstream factors that when demethylated
489activate the genes seen in the RT-PCR array. For instance, our
490methylation data demonstrated SOX5 was demethylated in the
491combination treatment, which is known to regulate RhoB in the
492neural tube (48). As genes regulated by histone acetylation also
493contribute to the synergistic effect, genome-wide histone acety-
494lation analysis would be necessary to fully understand the
495mechanisms of action of the combination treatment. Nonethe-
496less, the differentially methylated genes speciﬁc in the combina-
497tion treatment underline the important contribution of demeth-
498ylation to the synergistic effect. This proﬁlemight serve as thebasis
499for the identiﬁcation of a methylation signature that is predictive
500of clinical response as shown in myelodysplastic syndrome (49)
501or to a limited extent suggested recently in CTCL (50).
502In summary, there has been no common functional mutation
503or genetic aberration identiﬁed to be responsible for malignant
504transformation of T cells in CTCL. Our data provide insight to
505unique methylation proﬁle alterations with potential predictive
506value due to the synergistic antiproliferative effects of combined
507romidepsin and azacitidine treatment in CTCL, and paves the
508road for combining these agents in clinical trials for advanced
509CTCL.
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